Stock PV3B EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Real-time Estimate Tradegate
Other stock markets
 09:40:22 2024-05-06 am EDT 		5-day change 1st Jan Change
10.81 EUR -40.89% Intraday chart for EyePoint Pharmaceuticals, Inc. -1.18% -14.76%
03:08pm Sector Update: Health Care Stocks Gain Pre-Bell Monday MT
02:57pm EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation
PU
Sector Update: Health Care Stocks Gain Pre-Bell Monday
MT
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint
MT
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
DJ
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
AQ
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board
CI
EyePoint Pharmaceuticals : Investor Presentation March 2024
PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Transcript : EyePoint Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell
MT
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M
MT
EyePoint Pharmaceuticals: Q4 Earnings Snapshot
AQ
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
AQ
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. PV3B Stock
  5. News EyePoint Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW